Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence

J R Farwell1, Y J Lee, D G Hirtz

  • 1University of Washington School of Medicine, Seattle.

Insights

Phenobarbital treatment for febrile seizures in children may lower IQ scores. These cognitive effects might persist even after discontinuing the medication, without improving seizure control.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Phenobarbital is a common treatment for pediatric febrile seizures.
  • Concerns exist regarding potential behavioral and cognitive adverse effects.

Purpose of the Study:

  • To evaluate the impact of phenobarbital on cognitive development in children with febrile seizures.
  • To compare intelligence quotients (IQs) between children treated with phenobarbital and those receiving a placebo.

Main Methods:

  • A randomized controlled trial involving 217 children aged 8–36 months with a history of febrile seizures.
  • Daily phenobarbital doses (4–5 mg/kg) were administered to one group, while the other received a placebo.
  • Cognitive assessments (IQs) were conducted after two years and six months post-treatment discontinuation.

Main Results:

  • After two years, the phenobarbital group showed a mean IQ 7.03 points lower than the placebo group (P=0.0068).
  • Six months after discontinuing phenobarbital, the mean IQ remained lower by 5.2 points (P=0.052).
  • No significant difference in seizure recurrence was observed between the groups.

Conclusions:

  • Phenobarbital use in treating febrile seizures is associated with a significant depression in cognitive performance.
  • The observed cognitive disadvantage may persist for months after drug cessation.
  • The cognitive impairment is not compensated by improved seizure prevention benefits.

Related Concept Videos

Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...